The low level of PD-1-expressing PBMCs at the early period of anti-melanoma treatment could be explained by engagement of most PD-1-expressing PBMCs by the intratumor environment due to binding to tumor PD-L1, which would have been freed had we obtained late-stage PBMCs. The gene discussed is CD274; the disease is neoplasm.